Special Issue

Study on the Complex Melanoma

Message from the Guest Editor

Melanoma, the deadliest form of skin cancer, remains one of the most difficult cancers to treat despite recent advances in targeted and immune-therapies. Several driver oncogenes and tumor suppressor genes have been linked with the onset and progression of melanoma in experimental model systems, but alterations in expression and signaling cascades have demonstrated the complexity of this disease, and much remains to be uncovered to improve therapeutic outcomes. This Special Issue on *Cancers* invites a range of papers, from original research articles to comprehensive reviews on melanoma.

Guest Editor

Prof. Dr. Suzie Chen

Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Deadline for manuscript submissions

25 August 2025



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/65458

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

